1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63 (6): 871–80.
2. Shirai T, Mikamo M et al. Real-world effect of gastroesophageal reflux disease on cough-related quality of life and disease status in asthma and COPD. Allergol Int 2015; 64 (1): 79–83.
3. Пасечников В.Д., Ивахненко О.И., Слинько Е.Н. и др. Гастроэзофагеальная рефлюксная болезнь с атипичными клиническими проявлениями. Гедеон Рихтер в СНГ. 2000; 3: 36–40. / Pasechnikov V.D., Ivakhnenko O.I., Slin'ko E.N. i dr. Gastroezofageal'naia refliuksnaia bolezn' s atipichnymi klinicheskimi proiavleniiami. Gedeon Rikhter v SNG. 2000; 3: 36–40. [in Russian]
4. Dixon MF, Axon ATR. Bile reflux gastritis and Barrett’s esophagus: Further evidence of a role for duodenogastro-oesophageal reflux? Gut 2001; 49: 359–63.
5. Kahrilas P, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
6. Cannon WB. The movements of the stomach, studied by means of the roentgen rays. J Boston Soc Med Sci 1898; 2: 59–66.
7. Hurtz (Hurst) AF. The Sensibility of the Alimentary Canal. London: Oxford University Press, 1911; p. 58–61.
8. Beaumont H, Bennink R, De Jong J et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441–51.
9. Kuiken S, van Den Elzen B, Tytgat G et al. Evidence for pooling of gastric secretions in the proximal stomach in humans using single photon computed tomography. Gastroenterology 2002; 123: 2157–8.
10. Hampson FC, Farndale A, Strugala V et al. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137–47.
11. Hampson FC, Jolliffe IG, Bakhtyari A et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm 2010; 36: 614–23.
12. Mandel KG, Daggy BP, Brodie DA et al. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669–90.
13. Kwiatek MA, Roman S, Fareeduddin A et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59–66.
14. Rohof W, Bennink R, Smout A et al. An alginateantacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11: 1585–91.
15. Thomas E, Wade A et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595–602.
16. Rohof WO, Bennink RJ, Boeckxstaens GE. Effect of PPI on the size, position and acidity of the postprandial acid pocket. Gastroenterology 2012; 124: S-92.
17. Strugala V, Dettmar PW, Sarratt K et al. A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med Res 2010; 38: 449–57.
18 Peikin SR First. Gastrointestinal Health. First Edition. Harper Perennial (Harper Collins Publishers) 1999: 40.
19 Ткаченко Е.И., Успенский Ю.П., Пахомова И.Г. и др. Гастроэзофагеальная рефлюксная болезнь: новое решение старой проблемы. Consilium Medicum. 2009; 8. / Tkachenko E.I., Uspenskii Iu.P., Pakhomova I.G. i dr. Gastroezofageal'naia refliuksnaia bolezn': novoe reshenie staroi problemy. Consilium Medicum. 2009; 8. [in Russian]

________________________________________________

1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63 (6): 871–80.
2. Shirai T, Mikamo M et al. Real-world effect of gastroesophageal reflux disease on cough-related quality of life and disease status in asthma and COPD. Allergol Int 2015; 64 (1): 79–83.
3. Pasechnikov V.D., Ivakhnenko O.I., Slin'ko E.N. i dr. Gastroezofageal'naia refliuksnaia bolezn' s atipichnymi klinicheskimi proiavleniiami. Gedeon Rikhter v SNG. 2000; 3: 36–40. [in Russian]
4. Dixon MF, Axon ATR. Bile reflux gastritis and Barrett’s esophagus: Further evidence of a role for duodenogastro-oesophageal reflux? Gut 2001; 49: 359–63.
5. Kahrilas P, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
6. Cannon WB. The movements of the stomach, studied by means of the roentgen rays. J Boston Soc Med Sci 1898; 2: 59–66.
7. Hurtz (Hurst) AF. The Sensibility of the Alimentary Canal. London: Oxford University Press, 1911; p. 58–61.
8. Beaumont H, Bennink R, De Jong J et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010; 59: 441–51.
9. Kuiken S, van Den Elzen B, Tytgat G et al. Evidence for pooling of gastric secretions in the proximal stomach in humans using single photon computed tomography. Gastroenterology 2002; 123: 2157–8.
10. Hampson FC, Farndale A, Strugala V et al. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137–47.
11. Hampson FC, Jolliffe IG, Bakhtyari A et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm 2010; 36: 614–23.
12. Mandel KG, Daggy BP, Brodie DA et al. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669–90.
13. Kwiatek MA, Roman S, Fareeduddin A et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59–66.
14. Rohof W, Bennink R, Smout A et al. An alginateantacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11: 1585–91.
15. Thomas E, Wade A et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595–602.
16. Rohof WO, Bennink RJ, Boeckxstaens GE. Effect of PPI on the size, position and acidity of the postprandial acid pocket. Gastroenterology 2012; 124: S-92.
17. Strugala V, Dettmar PW, Sarratt K et al. A randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments. J Int Med Res 2010; 38: 449–57.
18 Peikin SR First. Gastrointestinal Health. First Edition. Harper Perennial (Harper Collins Publishers) 1999: 40.
19 Tkachenko E.I., Uspenskii Iu.P., Pakhomova I.G. i dr. Gastroezofageal'naia refliuksnaia bolezn': novoe reshenie staroi problemy. Consilium Medicum. 2009; 8. [in Russian]

Г.С.Аникин*

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
ФГБУ Поликлиника №3 Управления делами Президента РФ. 129090, Россия, Москва, Грохольский пер., д. 31
*medi321@mail.ru

________________________________________________

G.S.Anikin*

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
Out-Patient Сlinic №3 of Administration of the President of Russian Federation of the Ministry of Health of the Russian Federation. 129090, Russian Federation, Moscow, Grokhol'skii per., d. 31
*medi321@mail.ru